Goldman Sachs’s Innoviva INVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-650,000
Closed -$6.96M 6880
2016
Q4
$6.96M Sell
650,000
-3,957,400
-86% -$41.5M ﹤0.01% 2767
2016
Q3
$50.6M Buy
4,607,400
+2,723,500
+145% +$31.8M 0.02% 1198
2016
Q2
$19.8M Buy
+1,883,900
New +$22.3M 0.01% 1792
2015
Q4
Sell
-53,000
Closed -$381K 7241
2015
Q3
$381K Buy
+53,000
New +$720K ﹤0.01% 5402
2015
Q2
Sell
-228,200
Closed -$3.59M 7338
2015
Q1
$3.59M Buy
228,200
+28,200
+14% +$427K ﹤0.01% 3217
2014
Q4
$2.83M Buy
+200,000
New +$3.01M ﹤0.01% 3510
2014
Q2
Sell
-37,230
Closed -$928K 7069
2014
Q1
$928K Sell
37,230
-260,858
-88% -$7.64M ﹤0.01% 4747
2013
Q4
$8.56M Buy
+298,088
New +$8.72M ﹤0.01% 2504

Other funds holding INVA

Goldman Sachs's INVA Position: Q1 2026 in Review

Goldman Sachs increased its Innoviva (INVA) stake by 42% in Q1 2026, buying an estimated $10.2M and bringing the position to 1,593,383 shares worth $37.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1821.

Goldman Sachs first reported a position in INVA in Q2 2013 and has held it in 52 quarters since. 286 funds tracked by Wall St. Rank hold INVA as of Q1 2026.

  • Goldman Sachs held 1,593,383 shares of Innoviva worth $37.1M as of Q1 2026.
  • Goldman Sachs bought 471,412 Innoviva shares in Q1 2026, an estimated $10.2M.
  • Innoviva made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #1821 holding.
  • Goldman Sachs first reported a position in Innoviva in Q2 2013 and has held it in 52 quarters since.
  • 286 funds tracked by Wall St. Rank held Innoviva as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.